H.C. Wainwright analyst Raghuram Selvaraju reiterates a Buy rating on BioSpecifics Technologies with a $65 price target after the company disclosed that its President Thomas Wegman has been diagnosed with glioblastoma and is undergoing treatment. The analyst expects the illness to have no meaningful impact on operations. He notes that Endo International (ENDP) continues to market Xiaflex for the treatment of Peyronie's disease and Dupuytren's contracture. The cellulite pivotal data readout in Q1 of 2019 could be the next major catalyst for BioSpecifics, Selvaraju tells investors in a research note.